

Ameet Sarpatwari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/20911/publications.pdf>

Version: 2024-02-01

97
papers

2,220
citations

331538

21
h-index

243529

44
g-index

98
all docs

98
docs citations

98
times ranked

2395
citing authors

#	ARTICLE	IF	CITATIONS
1	The High Cost of Prescription Drugs in the United States. JAMA - Journal of the American Medical Association, 2016, 316, 858.	3.8	445
2	Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood, 2009, 113, 1231-1240.	0.6	273
3	Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. Haematologica, 2010, 95, 1167-1175.	1.7	197
4	Practical, Legal, and Ethical Issues in Expanded Access to Investigational Drugs. New England Journal of Medicine, 2015, 372, 279-286.	13.9	125
5	Autologous ¹¹¹ In-labelled platelet sequestration studies in patients with primary immune thrombocytopenia (ITP) prior to splenectomy: a report from the United Kingdom ITP Registry. British Journal of Haematology, 2010, 151, 477-487.	1.2	70
6	Expressing findings from meta-analyses of continuous outcomes in terms of risks. Statistics in Medicine, 2011, 30, 2967-2985.	0.8	55
7	Comparative effectiveness of generic and brand-name medication use: A database study of US health insurance claims. PLoS Medicine, 2019, 16, e1002763.	3.9	55
8	Why Are Biosimilars Not Living up to Their Promise in the US?. AMA Journal of Ethics, 2019, 21, E668-678.	0.4	44
9	Progress and Hurdles for Follow-on Biologics. New England Journal of Medicine, 2015, 372, 2380-2382.	13.9	43
10	Competition and price among brand-name drugs in the same class: A systematic review of the evidence. PLoS Medicine, 2019, 16, e1002872.	3.9	42
11	The US Biosimilar Market: Stunted Growth and Possible Reforms. Clinical Pharmacology and Therapeutics, 2019, 105, 92-100.	2.3	41
12	Evaluating The Impact Of The Orphan Drug Act's Seven-Year Market Exclusivity Period. Health Affairs, 2018, 37, 732-737.	2.5	40
13	Strategies That Delay Market Entry of Generic Drugs. JAMA Internal Medicine, 2017, 177, 1665.	2.6	33
14	Reforming the Orphan Drug Act for the 21st Century. New England Journal of Medicine, 2019, 381, 106-108.	13.9	31
15	Experience With the Priority Review Voucher Program for Drug Development. JAMA - Journal of the American Medical Association, 2015, 314, 1687.	3.8	30
16	Variation in Prescription Drug Prices by Retail Pharmacy Type. Annals of Internal Medicine, 2019, 171, 605.	2.0	30
17	Value-Based Pricing and State Reform of Prescription Drug Costs. JAMA - Journal of the American Medical Association, 2017, 318, 609.	3.8	28
18	State Initiatives to Control Medication Costs – Can Transparency Legislation Help?. New England Journal of Medicine, 2016, 374, 2301-2304.	13.9	27

#	ARTICLE	IF	CITATIONS
19	Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study. <i>BMJ: British Medical Journal</i> , 2018, 361, k1180.	2.4	27
20	Impact of State Laws Restricting Opioid Duration on Characteristics of New Opioid Prescriptions. <i>Journal of General Internal Medicine</i> , 2019, 34, 2339-2341.	1.3	27
21	Health-related lifestyle in adults and children with primary immune thrombocytopenia (ITP). <i>British Journal of Haematology</i> , 2010, 151, 189-191.	1.2	22
22	Promoting Patient Interests in Implementing the Federal Right to Try Act. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 869.	3.8	22
23	Assessment of Variation in State Regulation of Generic Drug and Interchangeable Biologic Substitutions. <i>JAMA Internal Medicine</i> , 2021, 181, 16.	2.6	22
24	Using a Drug-Safety Tool to Prevent Competition. <i>New England Journal of Medicine</i> , 2014, 370, 1476-1478.	13.9	21
25	Ensuring Patient Privacy in Data Sharing for Postapproval Research. <i>New England Journal of Medicine</i> , 2014, 371, 1644-1649.	13.9	19
26	The Impact Of Price Regulation On The Availability Of New Drugs In Germany. <i>Health Affairs</i> , 2019, 38, 1182-1187.	2.5	19
27	Utilization and Treatment Costs of Tumor Necrosis Factor Inhibitors After the Introduction of Biosimilar Infliximab in the United States. <i>Arthritis and Rheumatology</i> , 2020, 72, 1036-1038.	2.9	19
28	Removing ERISA's Impediment to State Health Reform. <i>New England Journal of Medicine</i> , 2018, 378, 5-7.	13.9	15
29	Missed Opportunities on Emergency Remdesivir Use. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 331.	3.8	15
30	Barriers To US Biosimilar Market Growth: Lessons From Biosimilar Patent Litigation. <i>Health Affairs</i> , 2021, 40, 1198-1205.	2.5	15
31	The FDA Amendments Act of 2007 "Assessing Its Effects a Decade Later. <i>New England Journal of Medicine</i> , 2018, 379, 1097-1099.	13.9	14
32	Paying Physicians to Prescribe Generic Drugs and Follow-On Biologics in the United States. <i>PLoS Medicine</i> , 2015, 12, e1001802.	3.9	13
33	Generic Versions of Narrow Therapeutic Index Drugs: A National Survey of Pharmacists' Substitution Beliefs and Practices. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 1093-1099.	2.3	13
34	Forbidden and Permitted Statements about Medications "Loosening the Rules. <i>New England Journal of Medicine</i> , 2015, 373, 967-973.	13.9	12
35	Postmarket Safety Communication for Protection of Public Health: A Comparison of Regulatory Policy in Australia, Canada, the European Union, and the United States. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1424-1442.	2.3	12
36	FDA and EMA Biosimilar Approvals. <i>Journal of General Internal Medicine</i> , 2020, 35, 1908-1910.	1.3	11

#	ARTICLE	IF	CITATIONS
37	Cost to Medicare of Delayed Adalimumab Biosimilar Availability. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1050-1056.	2.3	11
38	Evaluation of Socioeconomic Status Indicators for Confounding Adjustment in Observational Studies of Medication Use. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1513-1521.	2.3	10
39	Sponsorship and Funding for Gene Therapy Trials in the United States. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 890.	3.8	10
40	Active Surveillance of Follow-on Biologics: A Prescription for Uptake. <i>Drug Safety</i> , 2017, 40, 105-108.	1.4	9
41	Benefits, Limitations, and Value of Abuse-Deterrent Opioids. <i>JAMA Internal Medicine</i> , 2018, 178, 131.	2.6	9
42	Mitigating Health Risks of Prescription Drugs. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 651.	3.8	9
43	Changes in Utilization of Generic Angiotensin Receptor Blockers Following Product Recalls in the United States. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 87.	3.8	9
44	Revisiting the National Institutes of Health Fair Pricing Condition: Promoting the Affordability of Drugs Developed With Government Support. <i>Annals of Internal Medicine</i> , 2020, 172, 348-350.	2.0	9
45	The characteristics of patents impacting availability of biosimilars. <i>Nature Biotechnology</i> , 2022, 40, 22-25.	9.4	9
46	A Survey of Patients' Perceptions of Pill Appearance and Responses to Changes in Appearance for Four Chronic Disease Medications. <i>Journal of General Internal Medicine</i> , 2019, 34, 420-428.	1.3	8
47	A qualitative study of biosimilar manufacturer and regulator perceptions on intellectual property and abbreviated approval pathways. <i>Nature Biotechnology</i> , 2020, 38, 1253-1256.	9.4	8
48	Frequency of First Generic Drug Approvals With "Skinny Labels" in the United States. <i>JAMA Internal Medicine</i> , 2021, 181, 995-997.	2.6	8
49	Regulatory authority and clinical acceptability: Physicians' responses to regulatory drug safety warnings. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 713-722.	1.1	8
50	Ethical and Practical Considerations in Removing Black Box Warnings from Drug Labels. <i>Drug Safety</i> , 2016, 39, 709-714.	1.4	7
51	Six-Month Market Exclusivity Extensions To Promote Research Offer Substantial Returns For Many Drug Makers. <i>Health Affairs</i> , 2017, 36, 362-370.	2.5	7
52	An Incomplete Prescription. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 2373.	3.8	7
53	Accounting for US public funding in drug development: how can we better balance access, affordability, and innovation?. <i>BMJ, The</i> , 2020, 371, m3841.	3.0	7
54	Communicating emerging risks of SGLT2 inhibitors—timeliness and transparency of medicine regulators. <i>BMJ, The</i> , 2020, 369, m1107.	3.0	7

#	ARTICLE	IF	CITATIONS
55	Comparing Onset of Biosimilar Versus Generic Competition in the United States. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 1308-1314.	2.3	7
56	Ensuring Safe Access to Mifepristone During the Pandemic and Beyond. <i>Annals of Internal Medicine</i> , 2021, 174, 105-106.	2.0	7
57	A Multi-modal Approach to Evaluate the Impact of Risk Evaluation and Mitigation Strategy (REMS) Programs. <i>Drug Safety</i> , 2021, 44, 743-751.	1.4	7
58	The Case for Reforming Drug Naming: Should Brand Name Trademark Protections Expire upon Generic Entry?. <i>PLoS Medicine</i> , 2016, 13, e1001955.	3.9	7
59	State Restrictions on Mifepristone Access – The Case for Federal Preemption. <i>New England Journal of Medicine</i> , 2022, , .	13.9	7
60	Patient and Caregiver Experiences With and Perceptions of Risk Evaluation and Mitigation Strategy Programs With Elements to Assure Safe Use. <i>JAMA Network Open</i> , 2022, 5, e2144386.	2.8	7
61	Unwanted Advice? Frequency, Characteristics, And Outcomes Of Negative Advisory Committee Votes For FDA-Approved Drugs. <i>Health Affairs</i> , 2022, 41, 713-721.	2.5	7
62	Influence of drug safety advisories on drug utilisation: an international interrupted time series and meta-analysis. <i>BMJ Quality and Safety</i> , 2022, 31, 179-190.	1.8	6
63	Recalibrating Privacy Protections to Promote Patient Engagement. <i>New England Journal of Medicine</i> , 2017, 377, 1509-1511.	13.9	5
64	Effect of Lawyer-Submitted Reports on Signals of Disproportional Reporting in the Food and Drug Administration’s Adverse Event Reporting System. <i>Drug Safety</i> , 2019, 42, 85-93.	1.4	5
65	Tepid Steps on Drug Pricing. <i>JAMA Internal Medicine</i> , 2019, 179, 439.	2.6	5
66	Diabetes Drugs: List Price Increases Were Not Always Reflected In Net Price; Impact Of Brand Competition Unclear. <i>Health Affairs</i> , 2021, 40, 772-778.	2.5	5
67	Regulatory Solutions to the Problem of High Generic Drug Costs. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv179.	0.4	4
68	The Supreme Court Ruling in <i>Sandoz v Amgen</i> . <i>JAMA Internal Medicine</i> , 2018, 178, 5.	2.6	4
69	New Drug Formulations and Their Respective Generic Entry Dates. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019, 25, 218-224.	0.5	4
70	Grounding Value-Based Drug Pricing in Population Health. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 1290-1292.	2.3	4
71	Insulin access and affordability in the USA: anticipating the first interchangeable insulin product. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 360-362.	5.5	4
72	Changes in Erythropoiesis Stimulating Agent Use Under a Risk Evaluation and Mitigation Strategy (REMS) Program. <i>Drug Safety</i> , 2021, 44, 327-335.	1.4	4

#	ARTICLE	IF	CITATIONS
73	Risks to the 340B Drug Pricing Program Related to Manufacturer Restrictions on Drug Availability. JAMA - Journal of the American Medical Association, 2022, , .	3.8	4
74	Expanded Access to Investigational Drugs. New England Journal of Medicine, 2015, 372, 1473-1474.	13.9	3
75	The effect of federal and state off-label marketing investigations on drug prescribing: The case of olanzapine. PLoS ONE, 2017, 12, e0175313.	1.1	3
76	Clinical Development Times for Biosimilars in the United States. Mayo Clinic Proceedings, 2020, 95, 2152-2154.	1.4	3
77	Civil commitment for opioid misuse: do short-term benefits outweigh long-term harms?. Journal of Medical Ethics, 2022, 48, 608-610.	1.0	3
78	Promoting Biosimilar Competition by Revising Medicare Reimbursement Rules. JAMA Network Open, 2021, 4, e2134463.	2.8	3
79	Indication-Specific Generic Uptake of Imatinib Demonstrates the Impact of Skinny Labeling. Journal of Clinical Oncology, 2022, 40, 1102-1110.	0.8	3
80	Identifying potential prescription drug product hopping. Nature Biotechnology, 2021, 39, 414-417.	9.4	2
81	Preferences for and Experiences With Pill Appearance Changes: National Surveys of Patients and Pharmacists. American Journal of Managed Care, 2020, 26, 340-347.	0.8	2
82	COVID-19 antivirals must not affect HIV drug supply. Lancet HIV, the, 2022, 9, e7-e9.	2.1	2
83	Hydroxyzine Initiation Following Drug Safety Advisories on Cardiac Arrhythmias in the UK and Canada: A Longitudinal Cohort Study. Drug Safety, 2022, , 1.	1.4	2
84	Navigating the Dermatological Drug Cost Curve. JAMA - Journal of the American Medical Association, 2016, 315, 2724.	3.8	1
85	Factors Influencing Prescription Drug Costs in the United Statesâ€”Reply. JAMA - Journal of the American Medical Association, 2016, 316, 2431.	3.8	1
86	Efficacy of the Priority Review Voucher Program. JAMA - Journal of the American Medical Association, 2016, 315, 1660.	3.8	1
87	Orphan Drug Designation and Exclusivity for “Same Drugs”: Journal of Law, Medicine and Ethics, 2019, 47, 347-349.	0.4	1
88	Novelty of Active Ingredients in High-Cost Brand-Name Drugs. Journal of General Internal Medicine, 2020, 35, 2219-2221.	1.3	1
89	Corrections to Assessment of Variation in State Regulation of Generic Drug and Interchangeable Biologic Substitutions. JAMA Internal Medicine, 2021, 181, 144.	2.6	1
90	Health-Related Lifestyle among Adult & Pediatric Patients with Idiopathic Thrombocytopenic Purpura in the United Kingdom.. Blood, 2008, 112, 3435-3435.	0.6	1

#	ARTICLE	IF	CITATIONS
91	Preventing medical-deviceâ€borne outbreaks: High-level disinfection policy for duodenoscopes. Infection Control and Hospital Epidemiology, 2021, 42, 334-337.	1.0	1
92	Generic Competition for Drugs Treating Rare Diseases. Journal of Law, Medicine and Ethics, 2020, 48, 789-795.	0.4	1
93	COVID-19 Vaccine Boosters for All Adults: An Optimal U.S. Approach?. Annals of Internal Medicine, 2022, 175, 280-282.	2.0	1
94	State Laws and Generic Substitution in the Year After New Generic Competition. Value in Health, 2022, , .	0.1	1
95	Development of a National Public Pharmaceutical Research and Development Institute. Journal of Law, Medicine and Ethics, 2020, 48, 225-227.	0.4	0
96	Substitution of Generic Drugs and Biosimilarsâ€Reply. JAMA Internal Medicine, 2021, 181, 568.	2.6	0
97	The implications of Industry-Funded Disease Awareness Campaigns in the Rare Disease Setting. Mayo Clinic Proceedings, 2021, 96, 2305-2308.	1.4	0